CRVS Stock Overview
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
Corvus Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.02|
|52 Week High||US$3.41|
|52 Week Low||US$0.69|
|1 Month Change||18.06%|
|3 Month Change||12.34%|
|1 Year Change||-67.10%|
|3 Year Change||-76.28%|
|5 Year Change||-90.35%|
|Change since IPO||-92.84%|
Recent News & Updates
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn RateAug 14
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In GrowthApr 05
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash WiselyDec 15
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business GrowthAug 26
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?May 08
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More SharesFeb 19
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn SituationFeb 07
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks LikeDec 16
|CRVS||US Biotechs||US Market|
Return vs Industry: CRVS underperformed the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: CRVS underperformed the US Market which returned -14.9% over the past year.
|CRVS Average Weekly Movement||9.1%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: CRVS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CRVS's weekly volatility (9%) has been stable over the past year.
About the Company
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.
Corvus Pharmaceuticals, Inc. Fundamentals Summary
|CRVS fundamental statistics|
Is CRVS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CRVS income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.87|
|Net Profit Margin||0.00%|
How did CRVS perform over the long term?See historical performance and comparison